Acute thrombocytopenia: An uncommon complication occurring following transarterial chemoembolization in a patient with neuroendocrine hepatic metastases

Xie, Pingkun; Zheng, Yuxin

doi:10.3892/ol.2015.3232

Cited by 2 publications

(3 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In that patient, the PLT count was 186x10 9 /l prior to TACE and decreased to 7x10 9 /l after TACE, but the WBC count remained unchanged. Biochemical examinations revealed that the PLT-related IgG increased, the patient was non-responsive to PLT transfusion, and the PLT count returned to normal with dexamethasone treatment (29). In the present study, in 45 procedures (2.2%) puncture site bleeding developed after TACE, but the bleeding was controlled following adjustment of the artery compressor in all these cases, suggesting that the bleeding was caused by poor pressurization rather than the reduced PLT count.…”

Section: Discussionmentioning

confidence: 59%

Perioperative safety analysis of transcatheter arterial chemoembolization for hepatocellular carcinoma patients with preprocedural leukopenia or thrombocytopenia

Zhou

Zhang

Wang

et al. 2017

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract.Patients with hepatocellular carcinoma (HCC) exhibit a high incidence of concomitant cirrhosis with leukopenia and/or thrombocytopenia. In the present study, perioperative changes in the white blood cell (WBC) and platelet (PLT) counts and associated complications were investigated to assess the safety of transcatheter arterial chemoembolization (TACE) for HCC patients with preprocedural leukopenia or thrombocytopenia. The records of 1,461 HCC patients who received TACE between January 2012 and December 2013 were retrospectively reviewed. The incidence of complications during the perioperative period and changes in the WBC and PLT counts were recorded. A Chi -squared test was used to evaluate the associations between postoperative infection and preprocedural WBC count and between bleeding at the puncture site and preprocedural PLT count. The WBC count of the majority of the patients increased within 3 days and returned to the preprocedural level within 30 days after TACE. The PLT count decreased within 3 days and returned to the preprocedural level within 30 days after TACE. The major complications were liver decompensation (n=66), puncture site bleeding (n=45), infection (n=33), severe thrombocytopenia (n=8), upper gastrointestinal bleeding (n=6), tumor bleeding (n=4) and agranulocytosis (n=3). A Chi-squared test revealed that postoperative infection was not associated with preprocedural WBC count and puncture site bleeding was not associated with decreased PLT count due to hypersplenism. Therefore, TACE was found to be safe for HCC patients with preprocedural thrombocytopenia or leukopenia due to hypersplenism, with a low incidence of major complications during the perioperative period.

show abstract

Section: Discussionmentioning

confidence: 59%

Perioperative safety analysis of transcatheter arterial chemoembolization for hepatocellular carcinoma patients with preprocedural leukopenia or thrombocytopenia

Zhou

Zhang

Wang

et al. 2017

Molecular and Clinical Oncology

View full text Add to dashboard Cite

show abstract

“…Thrombocytopenia can occur as a result of myelosuppression, due to sepsis, as a result of an adverse reaction to pharmacological management, due to disseminated intravascular coagulation, etc. [9,10]. In this case, the patient did not have thrombocytopenia prior to the surgical intervention, and no chemotherapeutic drug was advocated as a part of management.…”

Section: Discussionmentioning

confidence: 87%

“…Yet this can only be diagnosed by antibody or kinetic verification tests, which were not performed in this case. Autoimmune thrombocytopenia is found in patients with solid tumors, including lung, prostate, breast, kidney, ovaries, and testis [10]. They will show elevated levels of platelet-associated IgG levels.…”

Section: Discussionmentioning

confidence: 99%

Occurrence of Immune Thrombocytopenic Purpura Following Enucleation of a Neuroendocrine Tumor of the Head of the Pancreas

Jazeer,

Garusinghe

2023

Cureus

View full text Add to dashboard Cite

Neuroendocrine tumors are growths occurring in various organs including the pancreas which contain endocrine tissue. Pancreatic neuroendocrine tumors are rare in occurrence with an incidence of <1 per 100,000 individuals. But the incidence is rising and the said tumors are becoming more common in the world. Herein we report a case of a 49-year-old female with a background history of poorly controlled type 2 diabetes mellitus for 7 years, dyslipidemia, and bronchial asthma for 19 years on regular inhaler therapy presenting with a history of back pain for 3 months duration. With serial investigations, she was found to have a neuroendocrine tumor involving the head of the pancreas with no local infiltration and distant metastases. Whipple's procedure was performed after which she developed thrombocytopenia from postoperative day 1 itself. Following this, she was diagnosed as having immune thrombocytopenic purpura and being managed with oral corticosteroids, after which she made a successful recovery from the acute condition but with multiple relapses from time to time.

show abstract

Acute thrombocytopenia: An uncommon complication occurring following transarterial chemoembolization in a patient with neuroendocrine hepatic metastases

Cited by 2 publications

References 14 publications

Perioperative safety analysis of transcatheter arterial chemoembolization for hepatocellular carcinoma patients with preprocedural leukopenia or thrombocytopenia

Perioperative safety analysis of transcatheter arterial chemoembolization for hepatocellular carcinoma patients with preprocedural leukopenia or thrombocytopenia

Occurrence of Immune Thrombocytopenic Purpura Following Enucleation of a Neuroendocrine Tumor of the Head of the Pancreas

Contact Info

Product

Resources

About